NU-0129 (Au-core SNA carrying siRNA against BCL2L12) completed a first-in-human Phase 0 study in recurrent GBM, demonstrating intratumoral delivery and target engagement after IV dosing prior to resection (NCT03020017). The gene discussed is BCL2L12; the disease is glioblastoma.